Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Complex Generics: Pre-Competitive Research Collaborations To Get US FDA Funding Boost

Executive Summary

Center for Research on Complex Generics will be similar to the Critical Path Institute; training sessions for industry could begin in January.

You may also be interested in...



FDA And Industry Set Out GDUFA III Priorities

Both first-cycle approvals and priority assessment improvements have been the subject of questions and criticism as the FDA and industry attempt to boost generic competition.

GDUFA III: First-Cycle Approval, Priority Assessment Improvements Are Early Priorities

Both issues have been the subject of questions and criticism as the FDA and industry attempt to boost generic competition.

Generic Drug Bioequivalence Study Interruptions Not Just A Coronavirus Problem

US FDA should create a policy to help save troubled studies, because failure can kill generic development programs, Lachman Consultants Michelle Ryder suggests.

Related Content

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel